Answers are grounded in this paper and cite their sources.
T cells are expanded and express GZMK/B. Our data suggest nivolumab drives both maintenance and replacement of previously expanded T cell clones, but only maintenance correlates with response. We hypothesize that maintenance and boosting of a pre-existing response is a key element of anti-PD-1 mode of action.
No takes yet. Share an insight, caveat, or question.
Au et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: